GlassScriptPhysician profile
David J Sharon
NPI 1730299041
$1,874.42
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,488 · 2020: $386.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $334.95 | 2019-2020 | |
| Genentech USA, INC. | $229.77 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $214.76 | 2019-2020 | |
| Janssen Biotech, INC. | $196.56 | 2019-2020 | |
| Seagen INC. | $122.71 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $107.68 | 2019-2020 | |
| Pfizer INC. | $75.32 | 2019 | |
| Puma Biotechnology, INC. | $74.76 | 2019-2020 | |
| Eisai INC. | $66.93 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $63.68 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $47.70 | 2019-2020 | |
| Lilly USA, LLC | $42.45 | 2019-2020 | |
| Abbvie INC. | $39.75 | 2019-2020 | |
| Genzyme Corporation | $39.59 | 2019-2020 | |
| Celgene Corporation | $37.13 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.19 | 2019 | |
| Amgen INC. | $26.22 | 2019-2020 | |
| Astellas Pharma US INC | $23.98 | 2020 | |
| Dendreon Pharmaceuticals LLC | $17.56 | 2019 | |
| Dova Pharmaceuticals | $15.84 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.88 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $14.45 | 2019 | |
| Sanofi-Aventis U.S. LLC | $13.71 | 2020 | |
| Gilead Sciences, INC. | $13.50 | 2019 | |
| Exelixis INC. | $13.35 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Sharon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.